151 related articles for article (PubMed ID: 23852678)
1. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
[TBL] [Abstract][Full Text] [Related]
3. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.
Calcedo R; Vandenberghe LH; Gao G; Lin J; Wilson JM
J Infect Dis; 2009 Feb; 199(3):381-90. PubMed ID: 19133809
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus antibody profiles in newborns, children, and adolescents.
Calcedo R; Morizono H; Wang L; McCarter R; He J; Jones D; Batshaw ML; Wilson JM
Clin Vaccine Immunol; 2011 Sep; 18(9):1586-8. PubMed ID: 21775517
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.
Yu B; Zhou Y; Wu H; Wang Z; Zhan Y; Feng X; Geng R; Wu Y; Kong W; Yu X
J Med Virol; 2012 Sep; 84(9):1408-14. PubMed ID: 22825819
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China.
Sun C; Zhang Y; Feng L; Pan W; Zhang M; Hong Z; Ma X; Chen X; Chen L
Vaccine; 2011 May; 29(22):3837-41. PubMed ID: 21447314
[TBL] [Abstract][Full Text] [Related]
11. A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.
Liu Q; Huang W; Nie J; Zhu R; Gao D; Song A; Meng S; Xu X; Wang Y
PLoS One; 2012; 7(3):e33392. PubMed ID: 22438922
[TBL] [Abstract][Full Text] [Related]
12. Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma.
Walz CM; Nakamura M; Fukunaga T; Jasiewicz Y; Edler L; Schlehofer JR; Tanaka Y
J Med Virol; 2001 Sep; 65(1):185-9. PubMed ID: 11505462
[TBL] [Abstract][Full Text] [Related]
13. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.
Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Pogoda JM; Provost R; Guerrero J; Hajjar RJ; Zsebo KM
Gene Ther; 2016 Mar; 23(3):313-9. PubMed ID: 26699914
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.
Ling C; Wang Y; Feng YL; Zhang YN; Li J; Hu XR; Wang LN; Zhong MF; Zhai XF; Zolotukhin I; Srivastava A; Ling CQ
J Integr Med; 2015 Sep; 13(5):341-6. PubMed ID: 26343106
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.
van der Marel S; Comijn EM; Verspaget HW; van Deventer S; van den Brink GR; Petry H; Hommes DW; Ferreira V
Inflamm Bowel Dis; 2011 Dec; 17(12):2436-42. PubMed ID: 21370319
[TBL] [Abstract][Full Text] [Related]
17. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
Fu H; Meadows AS; Pineda RJ; Kunkler KL; Truxal KV; McBride KL; Flanigan KM; McCarty DM
Hum Gene Ther Clin Dev; 2017 Dec; 28(4):187-196. PubMed ID: 29064732
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
Pilankatta R; Chawla T; Khanna N; Swaminathan S
J Med Virol; 2010 Mar; 82(3):407-14. PubMed ID: 20087930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
